Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
<p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to signific...
| Päätekijä: | |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Opinnäyte |
| Kieli: | English |
| Julkaistu: |
2021
|
| Aiheet: |